Petrenko Yuriy, Syková Eva, Kubinová Šárka
Department of Biomaterials and Biophysical Methods, Institute of Experimental Medicine AS CR v. v. i, Vídeňská 1083, 14220, Prague 4-Krč, Czech Republic.
Department of Neuroscience, Charles University, Second Faculty of Medicine, V Uvalu 84, 15006, Prague, Czech Republic.
Stem Cell Res Ther. 2017 Apr 26;8(1):94. doi: 10.1186/s13287-017-0558-6.
The efficiency of clinical trials involving transplantation of multipotent mesenchymal stromal cells (MSCs) is often insufficient due to harsh conditions present within the target tissue including hypoxia, low nutrient supply as well as inflammatory reactions. This indicates the necessity for optimization of cell-based therapy approaches which might include either modification of the cell manufacturing process or specific cell pretreatment procedures prior to transplantation. Recent reports confirm evidence that the aggregation of MSCs into three-dimensional (3D) multicellular spheroids results in enhancement of the overall therapeutic potential of cells, by improving the anti-inflammatory and angiogenic properties, stemness and survival of MSCs after transplantation. Such an MSCs spheroid generation approach may open new opportunities for the enlargement of MSCs applications in clinical research and therapy. However, the unification and optimization of 3D spheroid generation techniques, including the selection of appropriate clinical-grade culture conditions and methods for their large-scale production, are still of great importance. The current review addresses questions regarding therapeutic-associated properties of 3D multicellular MSCs spheroids in vitro and during preclinical animal studies, with special attention to the possibilities of translating these research achievements toward further clinical manufacturing and applications.
由于靶组织内存在诸如缺氧、营养供应不足以及炎症反应等恶劣条件,涉及多能间充质基质细胞(MSCs)移植的临床试验效率往往不足。这表明优化基于细胞的治疗方法很有必要,这可能包括改进细胞制造工艺或在移植前进行特定的细胞预处理程序。最近的报告证实,MSCs聚集形成三维(3D)多细胞球体可通过改善MSCs移植后的抗炎和血管生成特性、干性和存活率,从而增强细胞的整体治疗潜力。这种MSCs球体生成方法可能为扩大MSCs在临床研究和治疗中的应用带来新机遇。然而,3D球体生成技术的统一和优化,包括选择合适的临床级培养条件及其大规模生产方法,仍然至关重要。本综述探讨了关于3D多细胞MSCs球体在体外和临床前动物研究中的治疗相关特性的问题,特别关注将这些研究成果转化为进一步临床制造和应用的可能性。